https://www.biopharmawatch.com/news/EW/edwards-lifesciences-host-investor-event-tct BiopharmaWatch en 2026-10-05T10:00:00.000Z Edwards Lifesciences to Host Investor Event in Conjunction With TCT https://www.biopharmawatch.com/news/WST/west-highlight-industry-leadership-cphi-worldwide BiopharmaWatch en 2026-10-05T10:00:00.000Z West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide https://www.biopharmawatch.com/news/PCVX/vaxcyte-opus-1-phase-3-trial-results BiopharmaWatch en 2026-10-05T10:00:00.000Z Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/ALVO/fda-approves-additional-manufacturing-capacity-simlandi BiopharmaWatch en 2026-10-05T08:00:00.000Z FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® https://www.biopharmawatch.com/news/BMY/help-save-a-life-blood-donation-drive-bmy BiopharmaWatch en 2026-10-05T07:54:00.000Z Driving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-05 BiopharmaWatch en 2026-10-05T07:15:33.007Z SIL204 Phase 2/3 for Locally Advanced Pancreatic Cancer: Biotech Catalysts Oct 5, 2026 https://www.biopharmawatch.com/news/PCVX/vaxcyte-webcast-opus-1-phase-3-trial-data BiopharmaWatch en 2026-10-04T21:00:00.000Z Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-ovarian-cancer-bot-bal BiopharmaWatch en 2026-10-04T02:42:00.000Z Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026 https://www.biopharmawatch.com/news/AGEN/riassunto-agenus-segnala-una-sopravvivenza-tre-anni-stimata-al-48 BiopharmaWatch en 2026-10-04T02:42:00.000Z Riassunto: Agenus segnala una sopravvivenza a tre anni stimata al 48% con BOT+BAL nel tumore ovarico recidivante all'IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-rate-ovarian-cancer BiopharmaWatch en 2026-10-04T02:41:00.000Z Samenvatting: Agenus rapporteert een geschatte driejarige overleving van 48% met BOT+BAL bij recidiverende eierstokkanker tijdens IGCS 2026 https://www.biopharmawatch.com/news/AGEN/agenus-dreijahresueberlebensrate-eierstockkrebs BiopharmaWatch en 2026-10-04T02:40:00.000Z Agenus meldet auf der IGCS 2026 eine geschätzte Dreijahresüberlebensrate von 48 % mit BOT+BAL bei rezidivierendem Eierstockkrebs https://www.biopharmawatch.com/news/GMAB/genmab-rinatabart-sesutecan-phase-2-results-ovarian-cancer BiopharmaWatch en 2026-10-03T19:40:00.000Z Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/AGEN/agenus-three-year-survival-bot-bal-ovarian-cancer BiopharmaWatch en 2026-10-03T14:50:00.000Z Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026